An unusual abacavir reaction

AIDS

Volumn 22, Issue 12, 2008, Pages 1520-1522

  Fox, Julie ^a,b   Newton, Pippa ^a,b   Daly, Rosemarie ^a,b   Blume, Alison ^a,b   Marett, Brett ^a,b   Greene, Linda ^a,b   Winston, Alan ^a,b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CLARITHROMYCIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ISONIAZID; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PYRAZINAMIDE; RIFAMPICIN; TENOFOVIR; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ANOREXIA; CANDIDA ALBICANS; CASE REPORT; CD4 LYMPHOCYTE COUNT; COUGHING; DRUG WITHDRAWAL; EVENING DOSAGE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LETTER; LUNG TUBERCULOSIS; MALE; MORNING DOSAGE; NAUSEA; PRIORITY JOURNAL; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; FEVER; HUMANS; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 49849083952     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328305bd9e     Document Type: Letter

References (12)

1. Adverse drug reactions online information tracking drug analysis. http://www.mhra.gov.uk/home/groups/public/documents/ sentineldocuments/dap-1 130235880839.pdf.
2. Simmons P. Abacavir sulfate (Ziagen). Res Initiat Treat Action 1999; 5:8-10.
3. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
4. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 13:1419-1420.
5. Walensky RP, GoldbergJH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999; 13:999-1000.
6. Waters L, Mandalia S, Gazzard B, Nelson M. Prospective HLA-BM5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007; 21:2533-2534.
7. Reeves I, Churchill D, Fisher M. Screening for HLA-B-5701 reduces the frequency of abacavir hypersensitivity reactions [abstract 14.270.S Drug Information]. In: Program and Abstracts of the 8th International Workshop on Adverse Drug Reactions and ipodystrophy in HIV; 24-26 September 2006; San Francisco, CA, USA; 2007. pp. 707-708.
8. Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S, LaFon S. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 1999; 43: 603-608.
9. Barber TJ, Marett B, Waldron S, Portsmouth S, Mackie NE, Weston R, Winston A. Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice? AIDS 2007; 21:1823-1824.
10. Phillips E, Staszewski S, Arribas J, Fitch N, Givens N, on behalf of the PREDICT-1 Study Team. Characteristics of abacavir hypersensitivity diagnoses according to HLA-B*5701 status and subsequent abacavir patch test result. 11th European AIDS Conference; 24-27 October 2007; Madrid, Spain; 2007.
11. Rauch A, Noland D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin Infect Dis 2006; 43:99-102.
12. Mallal S, Nolan D, WittC, Masel G, Martin AM, Moore C, et al. Association between the presence of HLA-BM5701, HLADR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcrip-tase inhibitor abacavir. Lancet 2002; 359:727-732.